Бельдиев С. Н. к.м.н., доцент, кафедра терапии и кардиологии Егорова И. В. к.м.н., ассистент, кафедра терапии и кардиологии Гавриленко Н. Г. к.ф.н., доцент, кафедра иностранных и латинского языков Березина Е. И. к.м.н., доцент, кафедра терапии и кардиологии Медведева И. В. к.м.н., доцент, кафедра терапии и кардиологии Платонов Д. Ю. д.м.н., заведующий, кафедра терапии и кардиологии ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России
According to the results of several short-term randomized controlled trials (RCTs), nicorandil is not inferior in its antianginal efficacy to beta-blockers (BB), calcium channel blockers (CCB) and long-acting nitrates (LAN). At the same time, in some short-term RCTs, as well as in the long-term RCT IONA (2002), it was shown that antianginal efficacy of nicorandil as monotherapy or in combination with other antianginal drugs did not differ from placebo. Ability of nicorandil to reduce the risk of adverse cardiovascular events, demonstrated in the RCT IONA, requires confirmation in a long-term trial with a stronger primary endpoint and concomitant treatment that would meet the current guidelines for the management of patients with chronic coronary syndromes. In this regard, and also taking into account the proven ability of nicorandil to cause gastrointestinal ulcerations, European experts currently consider nicorandil as a drug that is inferior in priority of choice to the first-line antianginal drugs (BB, CCB) and, in some cases, to the second-line drugs (LAN, ivabradine, ranolazine, trimetazidine).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.